News and Announcements
Cellmid Limited (ASX: CDY) – Key European Patent for Anti-Midkine Antibodies Granted
- Published October 08, 2013 2:33PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Patent for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases granted in Europe
- Most important patent family in Cellmid’s cancer treatment program
- Second granted patent in global patent family
SYDNEY, Tuesday, 8 October 2013: Cellmid Limited (ASX: CDY) advises that the European Patent Office has granted one of Cellmid’s most important antibody patents, application EP07828015.3 (patent ’15.3) entitled “Antibody recognising C- domain of midkine” (expiry 2027). The granted claims cover Cellmid’s cancer program for antibodies and antibody fragments which bind to the important functional C-domain of growth factor midkine (MK). In particular, antibodies of any kind that bind to key MK C-domain epitopes are covered.
Significantly, patent ’15.3 also grants composition of matter claims for MK-specific antibodies, including Cellmid’s lead anti-cancer antibody. The granted claims also cover the use of any such antibody for prevention and treatment of cancer, autoimmune disease, inflammatory disease, and any disease attributed to cell migration.
To read the full ASX Release please click on the document below.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
